We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Protein Helps Neurons Maintain Dopamine Production in Models of Parkinson's Disease

By LabMedica International staff writers
Posted on 20 Oct 2016
Image: Diagram shows how the neuropeptide Prokineticin-2 (PK2) is rapidly induced during early stages of neurotoxic stress and secreted into extracellular spaces. PK2 is thought to act as a protective mechanism that helps neurons cope with Parkinson’s disease (Photo courtesy of Dr. Anumantha Kanthasamy, Iowa State University).
Image: Diagram shows how the neuropeptide Prokineticin-2 (PK2) is rapidly induced during early stages of neurotoxic stress and secreted into extracellular spaces. PK2 is thought to act as a protective mechanism that helps neurons cope with Parkinson’s disease (Photo courtesy of Dr. Anumantha Kanthasamy, Iowa State University).
A team of neurodegenerative disease researchers has identified a protein that seems to help neurons in the brain maintain dopamine production.

Investigators at Iowa State University (Ames, USA) have been studying Prokineticin-2 (PK2), a recently discovered secreted protein that regulates important physiological functions including olfactory biogenesis and circadian rhythms in the central nervous system.

They reported in the October 5, 2016, online edition of the journal Nature Communications that although in mouse models PK2 expression was low in the nigral system of the brain, its receptors were constitutively expressed on nigrostriatal neurons, and that PK2 expression was highly induced in nigral dopaminergic neurons during early stages of degeneration in multiple mouse models of Parkinson’s disease (PD).

Functional studies demonstrated that PK2 promoted mitochondrial biogenesis and activated ERK (Extracellular signal-regulated kinase) and Akt (Protein kinase B) survival signaling pathways, thereby driving neuroprotection. Importantly, PK2 overexpression was protective, whereas PK2 receptor antagonism exacerbated dopaminergic degeneration in experimental PD.

PK2 signaling protected against oxidative stress, mitochondrial dysfunction, and dopaminergic degeneration. Blocking PK2 signaling using a PK2 receptor antagonist increased dopaminergic degeneration in a PD mouse model, while overexpression of PK2 by adeno-associated virus (AAV) gene delivery was neuroprotective. PK2 expression was also found to be elevated in the substantia nigra (SN) of PD patients, corroborating PK2’s clinical relevance in human PD.

“Of the thousands and thousands of factors we tracked in our experiments, why was this protein expressed so highly?” said senior author Dr. Anumantha Kanthasamy, professor of veterinary medicine at Iowa State University. “The neurons use PK2 to cope with stress. It is an in-built protective mechanism.”

Related Links:
Iowa State University

New
Gold Member
Nucleic Acid Extractor System
NEOS-96 XT
Online QC Software
Acusera 24•7
New
Pipette Calibration System
Artel PCS®
New
HPV Molecular Test
BD Onclarity HPV Assay

Channels

Clinical Chemistry

view channel
Image: The findings point to the feasibility of a quick, noninvasive urine-based approach to support earlier decision-making in multiple psychiatric conditions (photo credit: Shutterstock)

Noninvasive Urine Test May Support Earlier Diagnosis of Psychiatric Disorders

Delays in diagnosing serious psychiatric conditions can leave patients without timely support and complicate treatment planning. For bipolar disorder, average time to diagnosis can exceed nine years, and... Read more

Molecular Diagnostics

view channel
Image: The schematic diagram links key MASLD, MASH, and MASLD-HCC molecular drivers to emerging multi‑omics biomarkers and therapeutic modalities, highlighting the current barriers in clinical translation and strategic solutions aimed at refined risk stratification and personalized medicine (Photo courtesy of ©Science China Press)

Emerging Biomarkers Advance Early Detection of MASLD and Liver Cancer Risk

Metabolic dysfunction-associated steatotic liver disease (MASLD) affects about 30% of people worldwide and can advance to metabolic dysfunction-associated steatohepatitis (MASH), fibrosis, cirrhosis, and... Read more
ADLM